ARS Pharmaceuticals (SPRY) EPS (Weighted Average and Diluted) (2021 - 2026)

ARS Pharmaceuticals has disclosed EPS (Weighted Average and Diluted) across 6 years of filings, most recently posting -$0.61 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.61, down 74.29% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.01 (down 1082.35% YoY), and the FY2025 annual result was -$1.74, down 2275.0% from the prior year.
• EPS (Weighted Average and Diluted) came in at -$0.61 for Q1 2026 at ARS Pharmaceuticals, down from -$0.42 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.89 in Q4 2022 to a low of -$0.61 in Q1 2026.
• The 5-year median for EPS (Weighted Average and Diluted) is -$0.2 (2024), against an average of -$0.17.
• Across the five-year window, EPS (Weighted Average and Diluted) soared 828.57% in 2024 and plunged 253.85% in 2025, its largest moves.
• ARS Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $0.89 in 2022, then slumped by 107.87% to -$0.07 in 2023, then jumped by 828.57% to $0.51 in 2024, then tumbled by 182.35% to -$0.42 in 2025, then sank by 45.24% to -$0.61 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at -$0.61 (Q1 2026), -$0.42 (Q4 2025), and -$0.52 (Q3 2025), per Business Quant data.